{"version":"1.0","type":"link","title":"T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma.","author_name":"Kelley RK 외","author_url":"https://prs-insight.online/author/Kelley%20RK","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/109540","thumbnail_width":1200,"thumbnail_height":630}